Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia

Phase 2 Unknown 200 enrolled Sheba Medical Center Stanley Medical Research Institute · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of the present study is to evaluate the effect of D-serine, added to antipsychotic treatment, on negative and cognitive symptoms in schizophrenia. The investigators are hypothesizing that D-serine will improve cognitive functioning and negative symptoms.

Timeline

Start: 2004-10
Primary completion: —
Completion: 2007-10

Outcome

Missed primary endpoint

paper improvement on SANS was 11.4% for d-serine vs 14.8% for placebo, F1,147=1.18, P=.32 PMID 22795211 ↗

paper improvement on MATRICS was 6.8% for d-serine vs 6.1% for placebo, F1,125=0.96, P=.39 PMID 22795211 ↗

paper This study did not find a significant difference between drug and placebo. PMID 22795211 ↗

Publications

Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, Abramovich Y, Amital D, Doron A, Konas S, Levkovitz Y, Liba D, Teitelbaum A, Mashiach M, Zimmerman Y. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012 Jun;73(6):e728-34. doi: 10.4088/JCP.11m07031.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	D-serine	Unknown	2 g	—